Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1954-1960

  Zhang, Hong ^a   Li, Zhihong ^a   Wang, Kaizhong ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Celecoxib; Non small cell lung cancer; Sorafenib

Indexed keywords

CELECOXIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; SORAFENIB; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL 2 GENE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVIN GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRAZOLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907294968     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3026     Document Type: Article

References (34)

1. Mendez M, Custodio A and Provencio M: New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis 3: 30-56, 2011.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int 2013: 964743, 2013.
4. Majeti BK, Lee JH, Simmons BH and Shojaei F: VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 13: 213, 2013.
5. Chen CT and Hung MC: Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am J Transl Res 5: 393-403, 2013.
6. Dempke WC, Suto T and Reck M: Targeted therapies for non-small cell lung cancer. Lung Cancer 67: 257-274, 2010.
7. Li J, Pan YY and Zhang Y: Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. Oncol Lett 5: 68-72, 2013.
8. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB and Bisen PS: Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 12: 1082-1093, 2011.
9. Kao J, Sikora AT and Fu S: Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets 9: 931-937, 2009.
10. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64: 2030-2038, 2004.
11. Jeon YW and Suh YJ: Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep 29: 819-825, 2013.
12. Cervello M, Bachvarov D, Lampiasi N, et al: Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One 8: e65569, 2013.
13. Morisaki T, Umebayashi M, Kiyota A, et al: Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Anticancer Res 33: 1387-1395, 2013.
14. Tai MH, Weng CH, Mon DP, Hu CY and Wu MH: Ultraviolet C irradiation induces different expression of cyclooxygenase 2 in NIH 3T3 cells and A431 cells: the roles of COX-2 are different in various cell lines. Int J Mol Sci 13: 4351-4366, 2012.
15. Fulzele SV, Chatterjee A, Shaik MS, Jackson T and Singh M: Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res 23: 2094-2106, 2006.
16. Murakami M, Zhao S, Zhao Y, et al: Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncol Lett 6: 667-672, 2013.
17. Boutros T, Chevet E and Metrakos P: Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60: 261-310, 2008.
18. Das M and Wakelee H: Targeting VEGF in lung cancer. Expert Opin Ther Targets 16: 395-406, 2012.
19. Pasqualetti G, Ricciardi S, Mey V, Del Tacca M and Danesi R: Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer 74: 197-205, 2011.
20. Giovannetti E, Labots M, Dekker H, et al: Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des 19: 927-939, 2013.
21. Ferrario A, Fisher AM, Rucker N and Gomer CJ: Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 65: 9473-9478, 2005.
22. Qiu R, Chen J, Sima J, Shen X, Liu D and Shen J: NS398 induces apoptosis in non-small cell lung cancer cells. J Cancer Res Clin Oncol 138: 119-124, 2012.
23. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY and Yin R: Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 7: e34100, 2012.
24. Kirkpatrick K, Ogunkolade W, Elkak A, et al: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18: 237-241, 2002.
25. Zhao Q, Wang C, Zhu J, et al: RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J Exp Clin Cancer Res 30: 26, 2011.
26. Falandry C, Canney PA, Freyer G and Dirix LY: Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol 20: 615-620, 2009.
27. Choe MS, Zhang X, Shin HJ, Shin DM and Chen ZG: Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4: 1448-1455, 2005.
28. Buchanan FG, Holla V, Katkuri S, Matta P and DuBois RN: Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67: 9380-9388, 2007.
29. Chong H, Vikis HG and Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 15: 463-469, 2003.
30. Anjum R and Blenis J: The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758, 2008.
31. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
32. Cuevas BD, Abell AN and Johnson GL: Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26: 3159-3171, 2007.
33. Peng CL, Guo W, Ji T, et al: Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 8: 1729-1736, 2009.
34. Lu X, Tang X, Guo W, Ren T and Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol 102: 821-826, 2010.